Millennium Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-167,782
| Closed | -$940K | – | 6588 |
|
|
2024
Q2 | $940K | Sell |
167,782
-90,082
| -35% | -$392K | ﹤0.01% | 4147 |
|
|
2024
Q1 | $1.35M | Sell |
257,864
-264,538
| -51% | -$1.45M | ﹤0.01% | 4052 |
|
|
2023
Q4 | $2.73M | Buy |
522,402
+174,870
| +50% | +$1.73M | ﹤0.01% | 3343 |
|
|
2023
Q3 | $5.48M | Buy |
347,532
+65,787
| +23% | +$1.18M | ﹤0.01% | 2609 |
|
|
2023
Q2 | $5.48M | Sell |
281,745
-15,721
| -5% | -$373K | ﹤0.01% | 2596 |
|
|
2023
Q1 | $8.44M | Buy |
297,466
+207,963
| +232% | +$6.17M | ﹤0.01% | 2125 |
|
|
2022
Q4 | $2.62M | Sell |
89,503
-75,140
| -46% | -$2.39M | ﹤0.01% | 3341 |
|
|
2022
Q3 | $4.35M | Sell |
164,643
-150,096
| -48% | -$5.51M | ﹤0.01% | 3028 |
|
|
2022
Q2 | $14M | Buy |
314,739
+302,291
| +2,428% | +$13.9M | 0.01% | 1656 |
|
|
2022
Q1 | $616K | Sell |
12,448
-403
| -3% | -$19.3K | ﹤0.01% | 4953 |
|
|
2021
Q4 | $654K | Sell |
12,851
-897
| -7% | -$46.5K | ﹤0.01% | 4806 |
|
|
2021
Q3 | $767K | Sell |
13,748
-53,159
| -79% | -$2.62M | ﹤0.01% | 4939 |
|
|
2021
Q2 | $2.86M | Sell |
66,907
-19,598
| -23% | -$809K | ﹤0.01% | 3504 |
|
|
2021
Q1 | $3.61M | Buy |
86,505
+23,909
| +38% | +$1.11M | ﹤0.01% | 2947 |
|
|
2020
Q4 | $2.92M | Buy |
62,596
+35,886
| +134% | +$1.68M | ﹤0.01% | 2924 |
|
|
2020
Q3 | $1.14K | Sell |
26,710
-85,555
| -76% | -$3.74M | ﹤0.01% | 3049 |
|
|
2020
Q2 | $5.39M | Buy |
112,265
+106,134
| +1,731% | +$5.3M | 0.01% | 1697 |
|
|
2020
Q1 | $282K | Buy |
+6,131
| New | +$308K | ﹤0.01% | 3209 |
|
|
2019
Q4 | – | Sell |
-29,021
| Closed | -$1.64M | – | 4713 |
|
|
2019
Q3 | $1.64M | Buy |
29,021
+18,102
| +166% | +$1.02M | ﹤0.01% | 2571 |
|
|
2019
Q2 | $608K | Sell |
10,919
-182,029
| -94% | -$9.49M | ﹤0.01% | 3097 |
|
|
2019
Q1 | $9.74M | Sell |
192,948
-91,805
| -32% | -$4.09M | 0.01% | 1281 |
|
|
2018
Q4 | $11.5M | Buy |
284,753
+273,294
| +2,385% | +$14.1M | 0.02% | 1041 |
|
|
2018
Q3 | $794K | Buy |
+11,459
| New | +$869K | ﹤0.01% | 2992 |
|
|
2018
Q1 | – | Sell |
-20,841
| Closed | -$1.11M | – | 4174 |
|
|
2017
Q4 | $1.11M | Buy |
+20,841
| New | +$1.16M | ﹤0.01% | 2640 |
|
|
2017
Q3 | – | Sell |
-86,245
| Closed | -$6.8M | – | 3948 |
|
|
2017
Q2 | $6.8M | Buy |
86,245
+82,662
| +2,307% | +$6.76M | 0.01% | 1291 |
|
|
2017
Q1 | $297K | Sell |
3,583
-71,649
| -95% | -$5.33M | ﹤0.01% | 3050 |
|
|
2016
Q4 | $5.97M | Buy |
+75,232
| New | +$5.46M | 0.01% | 1214 |
|
|
2016
Q3 | – | Sell |
-186,512
| Closed | -$7.24M | – | 3692 |
|
|
2016
Q2 | $7.24M | Buy |
186,512
+108,009
| +138% | +$4.5M | 0.02% | 1036 |
|
|
2016
Q1 | $3.18M | Buy |
78,503
+72,965
| +1,318% | +$4.63M | 0.01% | 1523 |
|
|
2015
Q4 | $491K | Buy |
+5,538
| New | +$437K | ﹤0.01% | 2649 |
|
|
2015
Q3 | – | Sell |
-11,154
| Closed | -$902K | – | 3796 |
|
|
2015
Q2 | $902K | Sell |
11,154
-23,097
| -67% | -$1.5M | ﹤0.01% | 2338 |
|
|
2015
Q1 | $1.44M | Buy |
+34,251
| New | +$972K | ﹤0.01% | 2154 |
|
|
2014
Q2 | – | Sell |
-12,900
| Closed | -$164K | – | 3986 |
|
|
2014
Q1 | $164K | Buy |
+12,900
| New | +$175K | ﹤0.01% | 3235 |
|
Other funds holding EGRX
NCM
ACM
Millennium Management's EGRX Position: Q3 2024 in Review
Millennium Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 167,782 shares — an estimated $940K sold.
Millennium Management first reported a position in EGRX in Q1 2014 and held it in 33 quarters. The position peaked at $14M in Q2 2022. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.
- Millennium Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- Millennium Management sold 167,782 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $940K.
- Millennium Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
- Millennium Management's Eagle Pharmaceuticals, Inc. position peaked at $14M in Q2 2022.
- 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.
Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.